Navigation Links
Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/31/2008

PRINCETON, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference at 9:20 a.m. ET on Thursday, February 7, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex Web site at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc.
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
2. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
3. Medarex to Present at the JPMorgan Small/Mid Cap Conference
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
6. Womans Day Presents the 5th Annual Red Dress Awards Honoring Women Who Are Leaders in the Fight Against Heart Disease
7. Moog to Present at Cowen & Co. Aerospace and Defense Conference on February 5, 2008
8. Center for Science Writings presents: Big Fat Lies: The Truth about Diet, Exercise and Obesity
9. Stryker to Present at Investor Conference
10. AMICAS to Present at UBS Global Healthcare Services Conference
11. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... York (PRWEB) May 25, 2013 ... litigation underway in U.S. District Court, Western District of ... According to a Case Management Order issued on ... the filing of contested motions in the Actos bladder ... motions. (In re: Actos Product Liability Litigation, MDL No. ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market (2012 – ... Materials, Packaging, & Geography: Trends & Forecasts” defines ... analysis and forecasting of the global revenue for ... restraining factors for the global food encapsulation markets ... market is segmented and revenue are forecasted on ...
(Date:5/25/2013)... 25, 2013 Providing patients with their best ... team of weight management professionals. But, aside from educating patients ... Diet Doc’s hCG diets also provide patients, who ... childhood like bullying, more control over their lives by achieving ... with the underlying factors of weight gain derived from earlier ...
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... patients who allegedly suffered serious, life-threatening episodes of internal bleeding ... federal litigation underway in U.S. District Court, Southern District of ... on the Court’s website, 818 Pradaxa side effect claims had ... 24, 2013. That’s up from 705 claims reported by ...
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 ... organization dedicated to brain cancer research and advocacy, comments ... for Extraterrestrial Physics, that shows incorporating cold atmospheric plasma ... glioblastoma cells. , According to a Science ... for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... to new therapeutic targets , , TUESDAY, June 24 (HealthDay ... factor in the development of B-cell lymphomas, one of ... with mice, researchers at the National Jewish Medical and ... the surface of B-cells can cooperate with the MYC ...
... 24 Behavioral Risk Management is an,important best ... message from,a survey conducted by the Disability Management ... in Behavioral Risk,Management., Additionally, survey results show ... emerging focus area to one that is showing ...
... programs due Aug. 7, WASHINGTON, June ... group for creation of accreditation standards and ... requests for quality standards,and measures for both ... 50 advisory committee members include employers, health ...
... leading brand of vitamin, mineral and dietary supplements hits, record milestone; ... ... health, ADA, Mich., June 24 NUTRILITE, the world,s leading,brand ... sales over the last 12 months as Amway/Quixtar,s message of,optimal health ...
... LONDON, June 24 NHS Choices ( http://www.nhs.uk ... a Live well guide on women,s,health aged 18-39 ... maintaining a,healthy lifestyle., Based on NHS accredited ... provides users with information about,walking to get healthy, ...
... Region of the American Red Cross is facing alarmingly ... of local hospitals. The,morning began with five of the ... zero O-, the universal blood type. In order,to meet ... Region should,maintain a minimum three-day supply of all eight ...
Cached Medicine News:Health News:Research Uncovers Clues to Lymphoma 2Health News:Behavioral Risk in the Workplace: Behavioral Risk Management Continues to be an Important Best Practice Area for Employers 2Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 2Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 3Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 4Health News:URAC Releases Standards and Measures for Wellness Programs for Public Comment 5Health News:NUTRILITE(TM) Passes $3 Billion Mark in Annual Sales 2Health News:NUTRILITE(TM) Passes $3 Billion Mark in Annual Sales 3
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
(Date:5/23/2013)... 2013  Texas, premier physician associations today announced the ... tools they need to provide demonstrably better and more ... marketplace. "I am confident the Physician Services ... Stephen L. Brotherton , MD, president ... doctors are determined to make health care ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... Agility is positioned to support ... to reduce medication and other ... workflow for pharmacy support staff ... blood products, lab specimens and ...
... Context-sensitive medicine is the ability of medical ... pre-determined ways based on what is happening ... associations a Radianse indoor positioning solution (IPS) ... it requires identity, location and time to ...
... VerdaSee Intelli-Storeroom™ was developed to create physically ... entrances and exits are converted to RFID ... RFID readers and antennas by VerdaSee's Field ... affixed to assets that are to be ...
... ability to track the movement of ... assets can be done. VerdaSee's "intellishelvess" ... Continuous cycle counting is possible with ... (RFID) technology makes this possible. VerdaSee ...
Medicine Products: